These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 31825140)

  • 21. Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel.
    Parsons MT; de la Hoya M; Richardson ME; Tudini E; Anderson M; Berkofsky-Fessler W; Caputo SM; Chan RC; Cline MS; Feng BJ; Fortuno C; Gomez-Garcia E; Hadler J; Hiraki S; Holdren M; Houdayer C; Hruska K; James P; Karam R; Leong HS; Martins A; Mensenkamp AR; Monteiro AN; Nathan V; O'Connor R; Pedersen IS; Pesaran T; Radice P; Schmidt G; Southey M; Tavtigian S; Thompson BA; Toland AE; Turnbull C; Vogel MJ; Weyandt J; Wiggins GAR; Zec L; Couch FJ; Walker LC; Vreeswijk MPG; Goldgar DE; Spurdle AB
    Am J Hum Genet; 2024 Sep; 111(9):2044-2058. PubMed ID: 39142283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
    Cline MS; Liao RG; Parsons MT; Paten B; Alquaddoomi F; Antoniou A; Baxter S; Brody L; Cook-Deegan R; Coffin A; Couch FJ; Craft B; Currie R; Dlott CC; Dolman L; den Dunnen JT; Dyke SOM; Domchek SM; Easton D; Fischmann Z; Foulkes WD; Garber J; Goldgar D; Goldman MJ; Goodhand P; Harrison S; Haussler D; Kato K; Knoppers B; Markello C; Nussbaum R; Offit K; Plon SE; Rashbass J; Rehm HL; Robson M; Rubinstein WS; Stoppa-Lyonnet D; Tavtigian S; Thorogood A; Zhang C; Zimmermann M; ; Burn J; Chanock S; Rätsch G; Spurdle AB
    PLoS Genet; 2018 Dec; 14(12):e1007752. PubMed ID: 30586411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
    Meng H; Yao L; Yuan H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(11):3044-3052. PubMed ID: 31957001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
    [No Abstract]   [Full Text] [Related]  

  • 25. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
    Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
    Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
    PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variant classification changes over time in BRCA1 and BRCA2.
    Mighton C; Charames GS; Wang M; Zakoor KR; Wong A; Shickh S; Watkins N; Lebo MS; Bombard Y; Lerner-Ellis J
    Genet Med; 2019 Oct; 21(10):2248-2254. PubMed ID: 30971832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
    Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
    Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
    Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    O'Mahony DG; Ramus SJ; Southey MC; Meagher NS; Hadjisavvas A; John EM; Hamann U; Imyanitov EN; Andrulis IL; Sharma P; Daly MB; Hake CR; Weitzel JN; Jakubowska A; Godwin AK; Arason A; Bane A; Simard J; Soucy P; Caligo MA; Mai PL; Claes KBM; Teixeira MR; Chung WK; Lazaro C; Hulick PJ; Toland AE; Pedersen IS; ; Neuhausen SL; Vega A; de la Hoya M; Nevanlinna H; Dhawan M; Zampiga V; Danesi R; Varesco L; Gismondi V; Vellone VG; James PA; Janavicius R; Nikitina-Zake L; Nielsen FC; van Overeem Hansen T; Pejovic T; Borg A; Rantala J; Offit K; Montagna M; Nathanson KL; Domchek SM; Osorio A; García MJ; Karlan BY; ; De Fazio A; Bowtell D; ; McGuffog L; Leslie G; Parsons MT; Dörk T; Speith LM; Dos Santos ES; da Costa AABA; Radice P; Peterlongo P; Papi L; Engel C; Hahnen E; Schmutzler RK; Wappenschmidt B; Easton DF; Tischkowitz M; Singer CF; Tan YY; Whittemore AS; Sieh W; Brenton JD; Yannoukakos D; Fostira F; Konstantopoulou I; Soukupova J; Vocka M; ; Chenevix-Trench G; Pharoah PDP; Antoniou AC; Goldgar DE; Spurdle AB; Michailidou K; ;
    Br J Cancer; 2023 Jun; 128(12):2283-2294. PubMed ID: 37076566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    Li Y; Chen L; Lv J; Chen X; Zeng B; Chen M; Guo W; Lin Y; Yu L; Hou J; Li J; Zhou P; Zhang W; Li S; Jin X; Cai W; Zhang K; Huang Y; Wang C; Fu F
    BMC Cancer; 2022 Nov; 22(1):1125. PubMed ID: 36324133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.